Free Trial
NASDAQ:MTVA

MetaVia Q1 2025 Earnings Report

MetaVia logo
$0.64 +0.02 (+3.04%)
As of 08/7/2025 04:00 PM Eastern

MetaVia EPS Results

Actual EPS
-$0.36
Consensus EPS
-$0.57
Beat/Miss
Beat by +$0.21
One Year Ago EPS
N/A

MetaVia Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MetaVia Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
12:00AM ET

MetaVia Earnings Headlines

MetaVia Extends Phase 1 Trial for Obesity Drug
REVEALED FREE: Our top 3 stocks to own in 2025 and beyond
Every time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).
See More MetaVia Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MetaVia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MetaVia and other key companies, straight to your email.

About MetaVia

MetaVia (NASDAQ:MTVA) is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

View MetaVia Profile

More Earnings Resources from MarketBeat